Akari Therapeutics Targets Mid — 2027 Start for AKTX — 101 Phase 1 Trial
Akari Therapeutics is advancing AKTX-101 through preclinical safety studies and manufacturing, targeting Phase 1 clinical development in mid-2027. Its PH1 payload is designed to disrupt RNA splicing in cancer cells, offering a different approach from commonly used ADC payloads. Clinical data already presented at major